The vitreous humor as a barrier to nanoparticle distribution

Journal of Ocular Pharmacology and Therapeutics

Volumn 29, Issue 2, 2013, Pages 143-150

  Mains, Jenifer ^a   Wilson, Clive G ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; BEVACIZUMAB; COLLAGEN TYPE 2; COLLAGEN TYPE 9; GLYCOSAMINOGLYCAN; GREPAFLOXACIN; HEPARIN; HYALURONIDASE; MELANIN; NANOPARTICLE; PEGAPTANIB; RANIBIZUMAB; SCHIFF BASE; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN;

ADENO ASSOCIATED VIRUS; AGING; AQUEOUS HUMOR; BIOCHEMICAL COMPOSITION; BLOOD RETINA BARRIER; CELL COMPARTMENTALIZATION; CELL MIGRATION; CONFOCAL MICROSCOPY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG PENETRATION; ELECTRON MICROSCOPY; EMBRYO DEVELOPMENT; EPIFLUORESCENCE MICROSCOPY; FLUOROPHOTOMETRY; GENE EXPRESSION; HUMAN; HYPEREMIA; INFLAMMATION; INTRAOCULAR DRUG ADMINISTRATION; LENS IMPLANT; LIQUEFACTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MUELLER CELL; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE; OPTICAL COHERENCE TOMOGRAPHY; OXYGEN TRANSPORT; PARTICLE SIZE; PHAGOCYTE; PHOTORECEPTOR; PIGMENT EPITHELIUM; RETINA; RETINA BLOOD VESSEL; RETINOPATHY; REVIEW; SALMONELLA TYPHIMURIUM; VITRECTOMY; VITREOUS BODY; VITREOUS BODY DETACHMENT;

AGING; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; PARTICLE SIZE; VITREOUS BODY;

EID: 84875026465     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2012.0138     Document Type: Review

References (57)

1. Patton, T.F., & Robinson, J.R. Quantitative precorneal disposition of topically applied pilcarpine nitrate in rabbit eyes. J. Pharm. Sci. 65:1295-1301, 1976.
2. Wood, R.W., Li, V.H.K., Kreuter, J., & Robinson, J.R. Ocular disposition of poly-hexyl-2-cyano[3-14C] acrylate nanoparticles in the albino rabbit. Int. J. Pharm. 23:175-183, 1985.
3. Bucolo, C., Maltese, A., Maugeri, F., et al. Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene. J. Pharm. Pharmacol. 56:841-846, 2004.
4. de Campos, A.M., Diebodl, Y., Carvalho, E.L., et al. Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm. Res. 21: 803-810, 2004.
5. Le Goff, M.M., & Bishop, P.N. Adult vitreous structure and postnatal changes. Eye. 22:1214-1219, 2008.
6. Spitzer, M.S., Mlynczak, T., Schultheiss, M., et al. Preservative-free triamcinolone acetonide injectable suspension versus "traditional" triamcinolone preparations: impact of aggregate size on retinal biocompatibility. Retina. 31:2050-2057, 2011.
7. Couch, S.M., & Bakri, S.J. Use of triamcinolone during vitrectomy surgery to visualize membranes and vitreous. Clin. Ophthalmol. 2:891-896, 2008.
8. Koeberle, M.J., Hughes, P.M., Skellern, G.G., & Wilson, C.G. Binding of memantine to melanin: influence of type of melanin and characteristics. Pharm. Res. 20:1702-1709, 2003.
9. Foulds, W.S. Is your vitreous is really necessary? The role of the vitreous in the eye with particular reference to retinal attachment, detachment and the mode of action of vitreous substitutes. Eye. 1:641-664, 1987.
10. Duke-Elder, W.S., Robertson, E.B., & Davson, H. Studies on the vitreous body 1. Biochem. J. 29:72-75, 1934.
11. Lee, S.S., Ghosn, C., Yu, Z., et al. Vitreous VEGF clearance is increased after vitrectomy. Invest. Ophthalmol. Vis. Sci. 51: 2135-2138, 2011.
12. Knudsen, L.L., Dissing, T., Hansen, M.N., & Nielsen-Kudsk, F. Ocular fluorescein kinetics before and after vitrectomy on swine. Graefes Arch. Clin. Exp. Ophthalmol. 239:832-839, 2001.
13. Stefánsson, E. Physiology of vitreous surgery. Graefes Arch. Clin. Exp. Ophthalmol. 247:147-163, 2009.
14. Kleinberg, T.T., Tzekov, R.T., Stein, L., et al. Vitreous substitutes: a comprehensive review. Surv. Ophthalmol. 56: 300-323, 2011.
15. Foos, R.Y. Vitreoretinal juncture; topographical variations. Invest. Ophthalmol. Vis. Sci. 11:801-808, 1972.
16. Kagemann, L., Wollstein, G., Ishikawa, H., et al. Persistence of Cloquet's canal in normal healthy eyes. Am. J. Ophthalmol. 142:862-864, 2006.
17. Jongebloed, W.L., & Worst, J.F. The cisternal anatomy of the vitreous body. Doc. Ophthalmol. 67:183-196, 1987.
18. Laude, A., Tan, L.E., Wilson, C.G., et al. Intravitreal therapy for neovascular age-related macular degeneration and interindividual variations in vitreous pharmacokinetics. Prog. Retin. Eye Res. 29:466-475, 2010.
19. Sebag, J. Seeing the invisible: the challenge of imaging vitreous. J. Biomed. Opt. 9:38-46, 2004.
20. Sebag, J. The Vitreous: Structure, Function, and Pathobiology. New York: Springer-Verlag; 1989.
21. Johnson, M. Perifoveal vitreous detachment and its macular complications. Trans. Am. Opthalmol. Soc. 103:537-567, 2005.
22. Halfer, W.M., & Mayer, U. Basement membranedependent survival of retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 46:2010-2014, 2005.
23. Abdelkader, E., & Lois, N. Internal limiting membrane peeling in vitreo-retinal surgery. Surv. Ophthalmol. 53: 368-396, 2008.
24. Wolter, J.R. Pores in the inner limiting membrane of the human retina. Acta Ophthalmol. 42:971-974, 1964.
25. Wilson, C.G., Tan, L.A., & Mains, J. Principles of retinal drug delivery from within the vitreous. In: Kompella, U.B., and Edelhauser, H.F., eds. Drug Product Development for the Back of the Eye. Arlington: AAPS Press; 2011; p. 125-158.
26. Dalkara, D., Kolstad, K.D., Caporale, N., et al. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol. Ther. 17:2096-2102, 2009.
27. Hindson, J., Gallagher, J.T., Halfter, W., & Bishop, P.N. Opticin binds to heparan and chondroitin sulfate proteoglycans. Invest. Ophthalmol. Vis. Sci. 46:4417-4423, 2005.
28. Bourges, J.L., Gautier, S.E., Delie, F., et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest. Ophthalmol. Vis. Sci. 44:3562-3569, 2003.
29. Heiduschka, P., Fietz, P.H., Hofmeister, S., et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest. Ophthalmol. Vis. Sci. 48:2814-2823, 2007.
30. Sebag, J. Age-related differences in the human vitreoretinal interface. Arch. Ophthalmol. 109:966-969, 1991.
31. Tan, L.E., Wilson, C.G., Burke, J., et al. Effects of vitreous liquefaction on the intravitreal distribution of sodium fluorescein, fluorescein dextran and fluorescent microparticles. Invest. Ophthalmol. Vis. Sci. 52:1111-1118, 2011.
32. Missel, P.J. Hydraulic flow and vascular clearance: influences on intravitreal drug delivery. Pharm. Res. 19:1636-1647, 2002.
33. Stocchino, A., Repetto, R., & Cafferata, C. Eye rotation induced dynamics of a Newtonian fluid within the vitreous cavity: the effect of the chamber shape. Phys. Med. Biol. 52:2021-2034, 2007.
34. Mark, H.H. Aqueous humour dynamics and the iris. Med. Hypotheses. 60:305-308, 2003.
35. Neal, R.E., Bettelheim, F.A., Lin, C., et al. Alterations in human vitreous humour following cataract extraction. Exp. Eye Res. 80:337-347, 2005.
36. Short, B.G. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol. Pathol. 36:49-62, 2008.
37. Wilson, C.G., Semenova, E.M., Hughes, P., & Olejnik, O. Eye structure and physiological function. In: Toiutou, E., and Barry, B.W., eds. Enhancement in Drug Delivery. New York: C R C Press; 2007; p. 473-488.
38. Pérez-Oliván, S., Pinilla, I., Bregante, M.A., et al. Grepafloxacin concentration in ocular tissues after intravenous infusion in rabbits with intraocular inflammation. Ophthalmic Res. 37:335-340, 2005.
39. Pannicke, T., Uckermanna, O., Iandiev, I., et al. Ocular inflammation alters swelling and membrane characteristics of rat Müller glial cells. J. Neuroimmunol. 161:145-154, 2005.
40. Mains, J., Wilson, C., & Urquhart, A. A pharmacokinetic study of a combination of beta adrenoreceptor antagonists-in the isolated perfused ovine eye. Eur. J. Pharm. Biopharm. 80:393-401, 2012.
41. Midelfart, A., Dybdahl, A., Muller, N., et al. Dexamethasone and dexamethasone phosphate detected by H and F NMR spectroscopy in the aqueous humour. Exp. Eye Res. 66: 327-337, 1998.
42. Mains, J., Wilson, C., & Urquhart, A. ToF-SIMS analysis of dexamethasone distribution -in the isolated perfused eye. Invest. Ophthalmol. Vis. Sci. 52:8413-8419, 2011.
43. Mains, J., Wilson, C., & Urquhart, A. ToF-SIMS analysis of ocular tissues reveals biochemical differentiation and drug distribution. Eur. J. Pharm. Biopharm. 79:328-333, 2011.
44. Atluri, H., & Mitra, A.K. Disposition of short-chain aliphatic alcohols in rabbit vitreous by ocular microdialysis. Exp. Eye Res. 76:315-320, 2003.
45. Lieleg, O., & Ribbeck, K. Biological hydrogels as selective diffusion barriers. Trends Cell. Biol. 21:539-551, 2011.
46. Sakurai, E., Ozeki, H., Kunou, N., & Ogura, Y. Effect of particle size of polymeric nanospheres on intravitreal kinetics. Ophthalmic Res. 33:31-36, 2001.
47. Raju, H.B., Hu, Y., Padgett, K.R., et al. Investigation of nanoparticles using magnetic resonance imaging after intravitreal injection. Clin. Exp. Ophthalmol. 40:100-107, 2012.
48. Soppimath, K.S., Aminabhavi, T.M., Kulkarni, A.R., and Rudzinski, W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release. 70:1-20, 2001.
49. Bejjani, R.A., BenEzra, D., Cohen, H., et al. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol. Vis. 11:124-132, 2005.
50. Kozak, Y., Adnrieux, K., Villarroya, H., et al. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur. J. Immunol. 34:3702-3712, 2004.
51. Kim, H.R., Andrieux, K., Gil, S., et al. Translocation of poly(ethylene glycol-c-hexadecyl)cyanoacrylate nanoparticles into the rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules. 8:793-799, 2007.
52. Kim, H., & Csaky, K.G. Nanoparticle-integrin antagonist C16Y peptide treatment of choroidal neovascularization in rats. J. Control. Release. 142:286-293, 2010.
53. Merodio, M., Irache, J.M., Valamanesh, F., & Mirshahi, M. Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats. Biomaterials. 23:1587-1594, 2002.
54. Pitkanen, L., Ruponen, M., Nieminen, J., & Urtti, A. Vitreous is a barrier in nonviral gene transfer by cationic lipids and polymers. Pharm. Res. 20:576-583, 2003.
55. Kim, H., Robinson, S.R., & Csaky, K.G. Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina. Pharm. Res. 26:329-337, 2008.
56. Koo, H., Moon, H., Han, H., et al. The movement of selfassembled amiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection. Biomaterials. 33:3485-3493, 2012.
57. Verma, A., & Stellacci, F. Effect of surface properties on nanoparticle-cell interactions. Small. 6:12-21, 2009.